文献速递免疫规划卫生政策与健康促进

评估英格兰持续开展孕妇百日咳免疫规划的影响:模型研究与成本效果分析

Evaluating the impact of a continued maternal pertussis immunisation programme in England: A modelling study and cost-effectiveness analysis.
PubMed 文献 · Vaccine · 2021-06-26

该研究用数学模型评估英格兰2019—2038年停止与继续孕妇百日咳免疫规划的健康经济影响,纳入婴儿住院与死亡、QALY损失及NHS直接医疗成本,贴现率3.5%。模型支持继续该规划,ICER为£14,500/QALY(2.5%与97.5%分位:£7,300/QALY至£32,400/QALY)。

要点

  • 继续孕妇百日咳免疫规划具成本效果,ICER为£14,500/QALY。
  • 停止规划年均婴儿住院估计972例,继续为308例。
  • £30,000/QALY阈值下,规划具成本效果的概率为96.2%。

核心结论

  • 模型支持继续孕妇百日咳免疫规划,否则疾病活动与婴儿死亡将回升至更高水平。
  • 该结果促使决策者决定在英国常规免疫规划中继续孕妇百日咳规划。

研究设计与样本

  • 采用数学模型估计英格兰2019—2038年婴儿百日咳相关住院数与死亡数。
  • 成本效果分析纳入婴儿(0—2月龄)存活或死亡、丧子父母及20—44岁女性百日咳的QALY损失。
  • NHS直接医疗成本包括婴儿住院、孕妇接种及女性疾病成本,成本与QALY按3.5%贴现。
  • 通过敏感性分析探讨增量成本效果比(ICER)的变化。

主要发现

  • 继续孕妇规划为具成本效果的干预,ICER为£14,500/QALY(2.5%与97.5%分位:£7,300/QALY至£32,400/QALY)。
  • 停止与继续规划相比,婴儿住院年均估计均值分别为972例(范围582至1489)与308例(184至471)。
  • 结果对停止孕妇规划时住院数与死亡数最为敏感。
  • 在£30,000/QALY成本效果阈值下,孕妇规划具成本效果的概率为96.2%。

临床怎么用

  • 可将继续孕妇百日咳免疫规划作为具有成本效果的公共卫生策略予以维持。
  • 政策决策可参考ICER及成本效果概率评估孕妇百日咳免疫规划的持续性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: An unexpected resurgence of pertussis cases and infant deaths was observed in some countries that had switched to acellular pertussis vaccines in the primary immunisation schedule. In response to the outbreaks, maternal pertussis vaccination programmes in pregnant women have been adopted worldwide, including the USA in 2011 and the UK in 2012. Following the success of the programme in England, we evaluated the health and economic impact of stopping versus continuing the maternal pertussis immunisation to inform public health policy making. METHODS: We used a mathematical model to estimate the number of infant hospitalisations and deaths related to pertussis in England over 2019-2038. Losses in quality-adjusted life years, QALYs, were considered for infants (aged 0-2 months) who survived or died from pertussis, bereaved parents (of infants who died from pertussis), and women with pertussis (aged 20-44 years). Direct medical costs to the National Health Service included infant hospitalisations, maternal vaccinations, and disease in women. Costs and QALYs were discounted at 3.5%. Changes in the incremental cost-effectiveness ratio, ICER, were explored in sensitivity analyses. RESULTS: The model supports continuing the maternal pertussis immunisation programme as a cost-effective intervention at an ICER of £14,500/QALY (2.5% and 97.5%-quantile: £7,300/QALY to £32,400/QALY). Stopping versus continuing the maternal programme results in an estimated mean of 972 (range 582 to 1489) versus 308 (184 to 471) infant hospitalisations annually. Results were most sensitive to the number of hospitalisations and deaths when stopping the maternal programme. At a cost-effectiveness threshold of £30,000/QALY, the probability of the maternal programme being cost-effective was 96.2%. CONCLUSION: Our findings support continuing the maternal pertussis vaccination programme as otherwise higher levels of disease activity and infant mortality are expected to return. These results have led policy makers to decide to continue the maternal programme in the UK routine immunisation schedule.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sandmann F, Jit M, Andrews N, et al. Evaluating the impact of a continued maternal pertussis immunisation programme in England: A modelling study and cost-effectiveness analysis. Vaccine. 2021. PMID: 34183204. doi:10.1016/j.vaccine.2021.06.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。